Units, Clicks? Novel Diabetes Combos Need A Measurement
Doses for Sanofi, Novo's insulin/GLP-1 combinations cannot be referred to simply by the insulin measurement, advisory committee members agree.
You may also be interested in...
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC
The latest drug development news and highlights from our FDA Performance Tracker.
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.